Xinpei Deng

2.6k total citations · 6 hit papers
51 papers, 1.7k citations indexed

About

Xinpei Deng is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Xinpei Deng has authored 51 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 16 papers in Cancer Research and 15 papers in Oncology. Recurrent topics in Xinpei Deng's work include RNA modifications and cancer (12 papers), Cancer-related molecular mechanisms research (8 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Xinpei Deng is often cited by papers focused on RNA modifications and cancer (12 papers), Cancer-related molecular mechanisms research (8 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Xinpei Deng collaborates with scholars based in China, Hong Kong and United States. Xinpei Deng's co-authors include Jindong Xie, Yutian Zou, Hailin Tang, Yuhui Tang, Shaoquan Zheng, W. H. Tian, Xiaoming Xie, Chau‐Wei Wong, Xinhua Xie and Linyu Wu and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and International Journal of Molecular Sciences.

In The Last Decade

Xinpei Deng

43 papers receiving 1.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery

2022 248 citations Yutian Zou, Jindong Xie et al. profile →
The Single‐Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer

2022 191 citations Yutian Zou, Feng Ye et al. Advanced Science profile →
N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer

2022 167 citations Yutian Zou, Shaoquan Zheng et al. Nature Communications profile →
Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer

2024 106 citations Xueqi Ou, Jindong Xie et al. Drug Resistance Updates profile →
Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies

2024 50 citations Jindong Xie, Xinpei Deng et al. SHILAP Revista de lepidopterología profile →
Cancer-associated fibroblast-derived extracellular vesicles: regulators and therapeutic targets in the tumor microenvironment

2025 20 citations Jindong Xie, Xinmei Lin et al. Cancer Drug Resistance profile →

Peers

Xinpei Deng

ONCOL

PRM

IMMUN

Jindong Xie China

Yuhui Tang China

Shaoquan Zheng China

Diego M. Marzese United States

Yanis Boumber United States

Ximing Xu China

Cailu Song China

Silvestre Vicent Spain

Giulia Bottai Italy

Jindong Xie China

Xinpei Deng

1.1k ×1.0

641 ×1.0

576 ×1.1

ONCOL

576 ×1.2

PRM

311 ×1.1

IMMUN

Citations per year, relative to Xinpei Deng Xinpei Deng (= 1×) peers Jindong Xie

Countries citing papers authored by Xinpei Deng

Since Specialization

Citations

This map shows the geographic impact of Xinpei Deng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xinpei Deng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xinpei Deng more than expected).

Fields of papers citing papers by Xinpei Deng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xinpei Deng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xinpei Deng. The network helps show where Xinpei Deng may publish in the future.

Co-authorship network of co-authors of Xinpei Deng

This figure shows the co-authorship network connecting the top 25 collaborators of Xinpei Deng. A scholar is included among the top collaborators of Xinpei Deng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xinpei Deng. Xinpei Deng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lin, Anqi, Aimin Jiang, Li Chen, et al.. (2025). Large language models in clinical trials: applications, technical advances, and future directions. BMC Medicine. 23(1). 563–563. 1 indexed citations

Jiang, Aimin, Weiming Mou, Dongqiang Zeng, et al.. (2025). Temporal evolution of large language models (LLMs) in oncology. Journal of Translational Medicine. 23(1). 1219–1219.

Zhang, Xiaoyu, Xiaoqing Zhang, Qing Bao, et al.. (2025). Cancer stem cell plasticity in shaping drug resistance landscapes in prostate cancer. Journal of Advanced Research.

Cai, Tingting, Tao Feng, Wei Zhang, et al.. (2025). Neutrophil extracellular traps–STC1 positive feedback loop promotes immune evasion and metastasis in bladder cancer. Journal for ImmunoTherapy of Cancer. 13(11). e012736–e012736.

Ma, Shu, et al.. (2025). Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications. Research. 8. 747–747. 6 indexed citations

Xie, Jindong, Xinmei Lin, Xinpei Deng, et al.. (2025). Cancer-associated fibroblast-derived extracellular vesicles: regulators and therapeutic targets in the tumor microenvironment. Cancer Drug Resistance. 8. 2–2. 20 indexed citations breakdown →

Deng, Xinpei, et al.. (2025). Disulfidptosis in cancer: from redox stress to therapeutic strategy. Cancer Gene Therapy. 33(1). 22–25.

Xie, Jindong, Bo Lin, Weihong Tian, et al.. (2024). Pan‐Cancer Single‐Cell and Spatial‐Resolved Profiling Reveals the Immunosuppressive Role of APOE+ Macrophages in Immune Checkpoint Inhibitor Therapy. Advanced Science. 11(23). e2401061–e2401061. 35 indexed citations

Deng, Xinpei, et al.. (2024). Natural products reverse cisplatin resistance in the hypoxic tumor microenvironment. Cancer Letters. 598. 217116–217116. 25 indexed citations

10.

Xie, Jindong, Anli Yang, Qianwen Liu, et al.. (2024). Single‐cell RNA sequencing elucidated the landscape of breast cancer brain metastases and identified ILF2 as a potential therapeutic target. Cell Proliferation. 57(11). e13697–e13697. 28 indexed citations

11.

Xie, Jindong, Xinpei Deng, Yi Xie, et al.. (2024). Multi‐omics analysis of disulfidptosis regulators and therapeutic potential reveals glycogen synthase 1 as a disulfidptosis triggering target for triple‐negative breast cancer. SHILAP Revista de lepidopterología. 5(3). e502–e502. 44 indexed citations

12.

Xu, Rong, Ashuai Du, Xinpei Deng, et al.. (2024). tsRNA-GlyGCC promotes colorectal cancer progression and 5-FU resistance by regulating SPIB. Journal of Experimental & Clinical Cancer Research. 43(1). 230–230. 29 indexed citations

13.

Ghasemian, Abdolmajid, Hamed Afkhami, Abdolreza Daraei, et al.. (2024). CircRNA‐associated ceRNA regulatory networks as emerging mechanisms governing the development and biophysiopathology of epilepsy. CNS Neuroscience & Therapeutics. 30(4). e14735–e14735. 21 indexed citations

14.

Xie, Jindong, Xinpei Deng, Yuhui Tang, et al.. (2024). Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies. SHILAP Revista de lepidopterología. 3(1). e156–e156. 50 indexed citations breakdown →

15.

Zou, Yutian, Anli Yang, Bo Chen, et al.. (2024). crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer. Drug Resistance Updates. 77. 101126–101126. 42 indexed citations

16.

Hu, Xiaoqian, Xinpei Deng, Jindong Xie, Hailin Tang, & Yutian Zou. (2023). Heterogeneous PD-L1 expression in metastases impacts immunotherapy response. EBioMedicine. 97. 104816–104816. 5 indexed citations

17.

Xie, Jindong, Xinpei Deng, Yuhui Tang, et al.. (2023). Circular RNA: A promising new star of vaccine. Journal of Translational Internal Medicine. 11(4). 372–381. 70 indexed citations

18.

Zou, Yutian, Feng Ye, Yanan Kong, et al.. (2022). The Single‐Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer. Advanced Science. 10(5). e2203699–e2203699. 191 indexed citations breakdown →

19.

Zou, Yutian, Shaoquan Zheng, Xinhua Xie, et al.. (2022). N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nature Communications. 13(1). 2672–2672. 167 indexed citations breakdown →

20.

Zou, Yutian, Shaoquan Zheng, Xinpei Deng, et al.. (2019). The Role of Circular RNA CDR1as/ciRS-7 in Regulating Tumor Microenvironment: A Pan-Cancer Analysis. Biomolecules. 9(9). 429–429. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact